ABRAHAM M. Y. NOMURA, M.D. Dr. P.H.; GRANT N. STEMMERMANN, M.D.; I. MICHAEL SAMLOFF, M.D.
Grant support: by contract N01 CP 61060 from the Biometry Branch, National Cancer Institute.
▸Requests for reprints should be addressed to Abraham M. Y. Nomura, M.D.; Japan-Hawaii Cancer Study, Kuakini Medical Center, 347 North Kuakini Street; Honolulu, HA 96817.
NOMURA AMY, STEMMERMANN GN, SAMLOFF IM. Serum Pepsinogen I as a Predictor of Stomach Cancer. Ann Intern Med. 1980;93:537-540. doi: 10.7326/0003-4819-93-4-537
Download citation file:
Published: Ann Intern Med. 1980;93(4):537-540.
Among 7498 Japanese men who were examined from 1967 to 1970, 48 were subsequently diagnosed with stomach cancer and had premorbid stored sera available for serum pepsinogen I analysis. The median interval between serum collection and diagnosis of cancer was 44.5 months (range, 3 to 103 months). A low pepsinogen I level was found in 15 of the 48 patients with stomach cancer and in only six (6.3%) of 96 matched control subjects (p < 0.001). All 15 patients with low pepsinogen I levels belonged to the subgroup of 38 who had the intestinal-mixed-other histologic types of gastric cancer. This finding indicates that a low serum pepsinogen I level is a subclinical marker of increased risk for these histologic types of gastric cancer.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Hematology/Oncology, Gastrointestinal Cancer, Gastric Cancer.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only